NewCardio receives European patent for wireless ECG technology
19 March 2008
NewCardio, Inc. (OTCBB: NWCI), a development-stage cardiac diagnostic
and services company, announced today that it has received a Certificate
of Grant from the European Patent Office covering CardioBip, its
proprietary device and methodology for transtelephonic transmission of
comprehensive ECG data.
The CardioBip is a hand-held device that can wirelessly transmit
12-lead ECG data and offers the potential for integration with popular
hand-held PDA platforms.
The patent award adds to the company's IP portfolio, which includes
US Patents awarded in 2007 for technology underlying its VisualECG and
QTinno products, and several US and international patent applications
currently under review. The patent application, with 33 claims covering
the device, is also being reviewed in the US, China, Japan, and Korea.
Dr Branislav Vajdic, chief executive officer of NewCardio, Inc.,
commented, “We believe the CardioBip technology has an important role to
play in detection and monitoring of potentially fatal cardiac diseases.
Thus, we are gratified by the European Patent Office’s broad grant of
patent rights. We look forward to hearing soon from other patent
offices, including the US Patent and Trademark Office. NewCardio is
committed to advancing the widely accepted 12-lead ECG to deliver
innovation to the cardiac sciences.”